Release Date ![[down]](http://us.i1.yimg.com/us.yimg.com/i/fi/down.gif) |
Contributor |
Author |
Title |
Pages |
Price |
StarMine Author Rating | More Info |
| EPS Accuracy * |
Portfolio Return ** |
| 10-Nov-09 | Emerging Growth Equities , Ltd. | Raymond A. Myers CFA | MDVN: On track for pivotal AD data in 4-5 months. | 10 | $25 | | | View Abstract |
| 10-Nov-09 | Emerging Growth Equities , Ltd. | Raymond A. Myers CFA | BIOC: EGE increases target to $8 | 7 | $25 | | | View Abstract |
| 4-Nov-09 | Emerging Growth Equities , Ltd. | Raymond A. Myers CFA | STAA: Profitable platform to leverage new products | 11 | $25 | | | View Abstract |
| 3-Nov-09 | Emerging Growth Equities , Ltd. | Raymond A. Myers CFA | PFWD: Progressing on Plan; EGE reiterates Buy. | 8 | $25 | | | View Abstract |
| 2-Nov-09 | Emerging Growth Equities , Ltd. | Raymond A. Myers CFA | CRY: margins muted by balance sheet progress | 9 | $25 | | | View Abstract |
| 29-Oct-09 | Emerging Growth Equities , Ltd. | Raymond A. Myers CFA | RTIX: recovery losing momentum. | 7 | $25 | | | View Abstract |
| 29-Oct-09 | Emerging Growth Equities , Ltd. | Raymond A. Myers CFA | MDVN: Astellas is a gateway to the large urology market | 10 | $25 | | | View Abstract |
| 23-Oct-09 | Emerging Growth Equities , Ltd. | Raymond A. Myers CFA | OMCM: Acquisitions support continued operating improvement | 8 | $25 | | | View Abstract |